MYUNGMOON Pharm (017180) Fundamentals 2026 — P/E 15.2x, Revenue Analysis | SniperIQ
MYUNGMOON Pharm (017180) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩40.8B, trading at ₩1220.00 on the KSC. This SniperIQ fundamentals page covers MYUNGMOON Pharm's valuation (P/E 15.2x, P/B 0.4x), profitability (net margin 1.5%), revenue (₩195.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is MYUNGMOON Pharm's market cap?
MYUNGMOON Pharm (017180) has a market capitalization of approximately ₩40.8B, trading at ₩1220.00 on the KSC. Market cap moves with the live share price.
What is MYUNGMOON Pharm's P/E ratio?
MYUNGMOON Pharm's trailing twelve-month P/E ratio is 15.2x, with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is MYUNGMOON Pharm?
MYUNGMOON Pharm runs a net profit margin of 1.5%, a gross margin of 56.5%, and an operating margin of 4.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does MYUNGMOON Pharm generate?
MYUNGMOON Pharm reported revenue of ₩195.2B for fiscal year 2025, with net income of ₩1.9B and earnings per share (EPS) of 56.7. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does MYUNGMOON Pharm pay a dividend?
MYUNGMOON Pharm does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is MYUNGMOON Pharm financially healthy?
MYUNGMOON Pharm carries a debt-to-equity ratio of 1.00x and a current ratio of 0.95x, with a market beta of 0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is MYUNGMOON Pharm a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MYUNGMOON Pharm (017180) the key facts are: market cap ₩40.8B, P/E 15.2x, revenue ₩195.2B, 52-week range 1115-2055. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track MYUNGMOON Pharm's full fundamentals live
Get MYUNGMOON Pharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.